Please login to the form below

Not currently logged in
Email:
Password:

WuXi and PRA form Chinese joint venture

Combine to form new China-focused independentCRO

Shanghai-based WuXi PharmaTech has teamed up with its US counterpart PRA for a joint venture that will see the two offer contract research services in WuXi's home territory.

The contract research organisations (CROs) will combine their clinical operations in China into a single CRO that will be jointly owned by the two companies.

The as-yet unnamed new CRO will have offices in Shanghai, Beijing and Guangzhou and cover all regions of the country.

Dr Ge Li, chairman and CEO of WuXi PharmaTech, said: "China's pharmaceutical market today is the third largest in the world and growing very rapidly.

“Biopharmaceutical companies increasingly need sophisticated clinical-trial management services to gather the highest-quality data in Chinese patients to complete Chinese and international regulatory filings as quickly and successfully as possible.”

The new venture aims to become the “clinical trial service provider of choice in China”, he added.

It's the second major joint venture for WuXi in recent months, following the September agreement between its WuXi AppTech subsidiary and AstraZeneca's MedImmune unit to bring an inflammatory disease candidate to the Chinese market.

WuXi's new deal will see it work with PRA to offer phase I-IV clinical trial services, including clinical trial monitoring, project management and regulatory strategy, to clients across China, Hong Kong and Macau.

WuXi will contribute clinical and regulatory experience to the joint venture from its China-based clinical organisation, and supply laboratory services.

Meanwhile, PRA will bring its global resources and clinical research expertise to the table, as well as supporting the venture with its China-based staff and global technology capabilities.

"PRA's global experience and technical expertise and WuXi's operational experience and knowledge in China are a perfect fit," said Colin Shannon, PRA's president and CEO.

"Clinical trials continue to expand in China, and this joint venture is another step we are taking to meet the needs of our clients by establishing a strong presence there.”

8th January 2013

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Hive

We're a healthcare communications agency that does things differently. We put patients at the heart of everything we do, while...

Latest intelligence

patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe's leading hub for life sciences innovation...

Infographics